From scientific research services, R & D to pharmacy and then to drug circulation, relevant enterprises in the pharmaceutical industry chain have gradually resumed production and operation in the process of returning to work and production.
The first financial reporter learned from many enterprises that scientific research service enterprises are returning to work and production to deliver scientific research reagents, raw materials and laboratory consumables to customers as soon as possible; R & D enterprises maintain a high on-the-job rate of R & D personnel and steadily promote R & D projects; After the pharmaceutical enterprises gradually return to work and production, the internal operation efficiency is gradually improved and the output is increased; Pharmacy stores should be opened as much as possible, using o2o platform, group purchase and other ways to alleviate the problem of residents’ difficulty in buying drugs.
Following the “white list” of the first batch of resumption of work and production, the first financial reporter learned that Maiwei biology and Shanghai Titan Scientific Co.Ltd(688133) etc. in the pharmaceutical industry chain have entered the “white list” of the second batch of resumption of work and production.
scientific research service enterprises: send scientific research reagents, raw materials and laboratory consumables to customers as soon as possible
Scientific research service enterprises are at the upstream of pharmaceutical research and development, providing scientific research institutes and enterprises with experimental equipment, consumables, scientific research reagents and other products.
Shanghai Aladdin Biochemical Technology Co.Ltd(688179) mainly engaged in R & D, production and sales of scientific research reagents. In addition to providing scientific research reagents for scientific research institutes and R & D departments of large and medium-sized enterprises all over the country, the company also reserves a large number of epidemic prevention products.
“In order to deliver scientific research reagents and epidemic prevention products to customers as soon as possible, the company has arranged some employees to work on site before sealing and control to ensure the normal progress of logistics delivery.” Shanghai Aladdin Biochemical Technology Co.Ltd(688179) scale.
Shanghai Aladdin Biochemical Technology Co.Ltd(688179) production base is located in Shanghai Chemical Industry Park in Fengxian, which has been included in the white list of key enterprises to resume work and production in Fengxian District Shanghai Aladdin Biochemical Technology Co.Ltd(688179) said that at present, the company has more than 70 people working on the site with closed-loop management to ensure smooth links in R & D, production, picking and delivery and logistics.
Shanghai Titan Scientific Co.Ltd(688133) mainly provides customers with one-stop product development services and some raw materials for production.
“When the seal control in Shanghai was started, the company coordinated and arranged a team of nearly 100 people to carry out closed-loop work in Songjiang fund according to the basic guarantee requirements for R & D, analysis and testing, warehousing and distribution, and formulated strict disinfection and sterilization process, antigen nucleic acid detection arrangement and life supporting arrangement, ensuring the provision of basic services to customers during the seal control period.” Shanghai Titan Scientific Co.Ltd(688133) means.
Shanghai Titan Scientific Co.Ltd(688133) told the first financial reporter that the company has entered the list of the second batch of enterprises to resume work and production. The company has improved the relevant return to work guarantee process, gradually increased the number of closed-loop personnel and distribution vehicles, improved the supporting ability of the company to serve customers, and better supported the return to work and production of downstream customers.
Guangzhou Jet Bio-Filtration Co.Ltd(688026) is to provide laboratory consumables for life science related services related to cells and viruses.
\u3000\u3000 “In order to solve the infection risk of epidemic prevention personnel and the comfortable working environment of wearing protective clothing, the company has successfully developed positive pressure protective clothing, positive pressure protective headgear and other products, which are expected to be put into the market in the short term to provide better protective equipment for epidemic prevention and control. At the same time, the company is also accelerating the research and development of ‘neck sticking’ material ‘ultrafiltration membrane bag’ of vaccine related enterprises. At present, it has entered the stage of sample trial production and is expected to be put into use in the near future The future will provide opportunities for vaccine manufacturers to import substitutes. ” Guangzhou Jet Bio-Filtration Co.Ltd(688026) indicates.
Guangzhou Jet Bio-Filtration Co.Ltd(688026) told reporters that during the epidemic period, a large number of product exports were greatly affected by shipping schedule and containers, which affected the order delivery of overseas customers. At the same time, the rising price of imported materials also increased the cost to the company. However, with the effective prevention and control of the epidemic in China and the resumption of work and production of relevant enterprises upstream and downstream of the industrial chain, the above impact has been greatly improved. At present, the scientific research and experiment work of the company is gradually restored, which ensures the sustainable operation of the company.
Suzhou Nanomicro Technology Co.Ltd(688690) mainly provides key separation and purification materials for large-scale production of pharmaceutical enterprises and high-quality microsphere raw materials that can be stably mass produced for in vitro diagnostic reagent manufacturers.
“Covid-19 epidemic was repeated from March to April, but due to the company’s layout in advance, there were some raw material inventories, and the company actively took relevant countermeasures such as personnel and materials, so the production did not stop.” Suzhou Nanomicro Technology Co.Ltd(688690) scale.
In terms of product transportation, Suzhou Nanomicro Technology Co.Ltd(688690) mainly takes three measures: first, the company looks for long-term cooperative cold chain vehicles and drivers to send important production materials to Shanghai; Second, for the procurement of raw materials from other places, the company sent transport vehicles to pick up the goods on site; Third, the company has special personnel responsible for deployment, application for pass and shuttle vehicles to and from the high-speed point.
R & D enterprise: steady progress of the project
Shanghai Medicilon Inc(688202) is a bio pharmaceutical preclinical comprehensive R & D service cro, which mainly provides a full range of new drug R & D services for pharmaceutical enterprises and other new drug R & D institutions.
“The company began to increase the storage of various materials in the middle and late March to ensure that the company has sufficient production material reserves during the sealing and control period. On the eve of Pudong sealing and control on March 28, the vice president of some R & D departments led the team, and a large number of employees at all levels of R & D departments have been stationed in the company. So far, there has been no shutdown during the sealing and control period.” D.
In mid April, Shanghai Medicilon Inc(688202) was listed on the “white list” of key enterprises to resume work and production. “The company immediately formulated the Shanghai Medicilon Inc(688202) resumption plan to organize the business employees who have not yet returned to work to return to work. At the same time, since the resumption of work, upstream raw material suppliers such as reagent consumables began to supply successively and replenish the company’s inventory in time.” Shanghai Medicilon Inc(688202) scale.
Shanghai Medicilon Inc(688202) said that the company’s three business segments (drug discovery, pharmaceutical research and preclinical research) have always maintained a high on-the-job rate of R & D personnel. At present, R & D projects are advancing steadily and the overall production and operation work is carried out steadily and orderly.
Nanjing Vazyme Biotech Co.Ltd(688105) is a key common technology platform established independently, which has successively entered the business fields of biological reagent and in vitro diagnosis, and can carry out the research and development of antibody drugs.
“On the one hand, the company provides key enzyme raw materials for many covid-19 nucleic acid detection reagent manufacturers in China. Up to now, the company has provided more than 1 billion copies of nucleic acid detection reagent enzyme raw materials, which is one of the main suppliers in China. On the other hand, the covid-19 antigen detection kit independently developed by the company was approved to be listed by the State Drug Administration on March 11, and has been put into front-line antigen detection.” Nanjing Vazyme Biotech Co.Ltd(688105) scale.
According to Nanjing Vazyme Biotech Co.Ltd(688105) introduction, in order to ensure the stable supply of epidemic prevention materials, the company’s core production base implements self closed management, and builds multiple automatic production lines to rapidly improve the production capacity. At present, the daily output can reach more than 5 million people, and coordinates the logistics distribution channel to transport the products to the front line on time and on demand.
“At present, the company’s capacity expansion is smooth, the capacity utilization is good, the orders are sufficient and can be delivered in time, and all production and operation work are under normal development.
” Nanjing Vazyme Biotech Co.Ltd(688105) scale.
pharmaceutical enterprises: increased output after resumption of work
Shanghai Yizhong Pharmaceutical Co.Ltd(688091) committed to the development of innovative drugs and related products. The company told the first financial reporter that at present, it has resumed work and production, and the relevant production workshops have basically resumed production. In strict accordance with the requirements of relevant documents, it has implemented site classification management, employee management, logistics management, epidemic prevention material reserve, emergency response plan and guarantee work.
“Since the resumption of work and production, the company has actively coordinated upstream and downstream suppliers and customers to predict and layout the procurement of raw materials and logistics delivery in advance, so as to minimize the impact on the company due to the long logistics time limit. In addition, the internal operation efficiency has been effectively alleviated after the resumption of work and production step by step, and is gradually improving.” Shanghai Yizhong Pharmaceutical Co.Ltd(688091) scale.
It is a commercial pharmaceutical enterprise. “In order to ensure the supply of drugs in the market, the company’s R & D and production business chains were in low load operation during the epidemic and did not stop production.” Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) said that at present, the company has realized point-to-point and gradual reception of employees’ return to work through the return to work electronic pass, carried out gap analysis of internal prevention and control guidelines, and improved the company’s epidemic prevention and control measures. If the control measures can be relaxed, it is expected to fully resume production and operation with zero risk in June.
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) said that after the gradual resumption of work and production, the production batch arrangement will be increased orderly after the increase of returning personnel, and the increase of output further ensures the delivery needs of products; The procurement of some materials also tries to strengthen communication with suppliers and logistics providers through more channels, and strive to solve the problems of supply and shipment.
Maiwei bio is also an innovative biopharmaceutical enterprise, whose main products are antibody drugs. Maiwei biology said that when it learned that it was to be sealed, the management of the company immediately launched an emergency response plan, including various preparations such as production raw material logistics, supplies required by the laboratory, and living logistics of stationed employees.
“The company has just been listed in the ‘white list’ of the second batch of key enterprises in Shanghai for resumption of work and production, and has formulated a comprehensive plan for resumption of work and production in the shortest time, including resumption of work and production process, employee return process, epidemic prevention and control work plan, closed management plan, material guarantee plan, emergency disposal process, etc.” Maiwei biological said that with the practical experience of closed-loop work more than a month ago, the company is very confident in all aspects of management of resumption of work and production.
circulation enterprise: pharmacy stores “should be open”
“Since the outbreak, Shanghai Pharmaceuticals Holding Co.Ltd(601607) Suide Road, fengrao Road, fenggong road and other bases have closed-loop management of hundreds of employees and supplied epidemic prevention materials to 42 public hospitals, front-line anti epidemic units, charities and streets in Shanghai.” Shanghai Pharmaceuticals Holding Co.Ltd(601607) scale.
According to the first financial reporter, since the outbreak, Shanghai Pharmaceuticals Holding Co.Ltd(601607) has supplied 177619 million masks, more than 12.09 million pairs of gloves, more than 6.365 million sets of medical protective clothing and isolation clothing, and more than 425 million nucleic acid antigen detection reagents.
In order to ensure patients’ immediate need for medication, Shanghai Pharmaceuticals Holding Co.Ltd(601607) its Fahrenheit pharmacy stores “should be fully opened”, a total of 138 returned to work and opened store online business; Its “Internet +” platform has opened up the supply chain for prescription orders of Internet hospitals, and 228000 orders have been completed since March 1.
Shanghai Pharmaceuticals Holding Co.Ltd(601607) stated that the company is fully promoting the resumption of production at the production base, with more than 1000 employees stationed in the plant. Up to now, 15 enterprises have started the process of resumption of work and production, of which 10 enterprises have officially resumed work and production, including Xinyi, Xinya, Shangyao leiyunshang, Xingling, Shangyao Zhongxi, Shangyao Cansino Biologics Inc(688185) , Hu qingyutang, Shangyao Qingbao, etc.
The subsidiaries of Jointown Pharmaceutical Group Co.Ltd(600998) Shanghai Jointown Pharmaceutical Group Co.Ltd(600998) Pharmaceutical Co., Ltd., Shanghai haoyaoshi pharmacy chain Co., Ltd., Shanghai Jointown Pharmaceutical Group Co.Ltd(600998) medical device Co., Ltd. and Shanghai Jointown Pharmaceutical Group Co.Ltd(600998) medical device supply chain Co., Ltd. have also resumed work and production.
“We continuously adhered to the distribution work and actively met the needs of drugs and equipment from the government, downstream customers and citizens. During this period, we supplied a large number of epidemic prevention materials, including 63 million reagent kits, 45 million masks, 14 million Lianhua Qingwen kits, 900000 Yupingfeng kits, etc. at the same time, we also fully supplied other drugs to meet the normal drug purchase needs of customers.” Jointown Pharmaceutical Group Co.Ltd(600998) indicates.
According to Jointown Pharmaceutical Group Co.Ltd(600998) introduction, at present, 370 stores of good pharmacists persist in business, covering all districts of Shanghai. They use o2o platform, group purchase and other forms to serve residents within 3km around the stores. The o2o business of a single store completes 500 orders per day, serves thousands of communities, and has completed the supply of more than 500000 orders, alleviating the problem of “it is difficult for residents to buy drugs”.
Lbx Pharmacy Chain Joint Stock Company(603883) large pharmacy is also solving the drug needs of patients. According to Wang Feng, general manager of Lbx Pharmacy Chain Joint Stock Company(603883) pharmacy Shanghai company, as of April 28, 69 stores were open in Shanghai, accounting for about 70% of the total number of stores, distributed in Pudong, Xuhui, Huangpu, Hongkou, Changning, Yangpu, Putuo, Jing’an, Baoshan and other districts.
“These stores are operating at a high load. On the basis of doing a good job in employee epidemic prevention management, the company tries to expand the drug purchase channels and meet the drug purchase needs of more residents as much as possible.” Wang Feng said.
